Financial reports
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
22 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
13 May 21
10-K
2020 FY
Annual report
16 Mar 21
Current reports
8-K
Completion of Acquisition or Disposition of Assets
1 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
30 May 23
8-K
Entry into a Material Definitive Agreement
24 May 23
8-K
Other Events
22 May 23
8-K
TCR2 Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
11 May 23
8-K
TCR2 Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
23 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
6 Mar 23
8-K
TCR2 Therapeutics Announces Pipeline Priorities for 2023
5 Jan 23
8-K
Departure of Directors or Certain Officers
3 Jan 23
Registration and prospectus
15-12G
Securities registration termination
12 Jun 23
POS AM
Prospectus update (post-effective amendment)
1 Jun 23
POS AM
Prospectus update (post-effective amendment)
1 Jun 23
POS AM
Prospectus update (post-effective amendment)
1 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jun 23
25-NSE
Exchange delisting
1 Jun 23
Proxies
DEFA14A
Additional proxy soliciting materials
24 May 23
DEFA14A
Additional proxy soliciting materials
22 May 23
DEFM14A
Proxy related to merger
20 Apr 23
DEFA14A
Additional proxy soliciting materials
1 Sep 22
DEF 14A
Definitive proxy
1 Sep 22
DEFA14A
Additional proxy soliciting materials
3 Sep 21
DEF 14A
Definitive proxy
3 Sep 21
DEFA14A
Additional proxy soliciting materials
14 Aug 20
DEF 14A
Definitive proxy
14 Aug 20
DEFA14A
Additional proxy soliciting materials
28 Aug 19
Other
EFFECT
Notice of effectiveness
6 Jun 23
EFFECT
Notice of effectiveness
6 Jun 23
EFFECT
Notice of effectiveness
6 Jun 23
EFFECT
Notice of effectiveness
24 Mar 22
EFFECT
Notice of effectiveness
29 Apr 20
CORRESP
Correspondence with SEC
24 Apr 20
UPLOAD
Letter from SEC
12 Mar 20
CT ORDER
Confidential treatment order
14 Feb 19
CERT
Certification of approval for exchange listing
13 Feb 19
EFFECT
Notice of effectiveness
13 Feb 19
Ownership
4
KEVIN C TANG
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
4
Change in insider ownership
5 Jun 23
4
Change in insider ownership
5 Jun 23
4
LUKE EVNIN
5 Jun 23
4
ANSBERT GADICKE
5 Jun 23
4
Andrew R Allen
1 Jun 23
4
Shawn Tomasello
1 Jun 23
4
Eric Sullivan
1 Jun 23
4
Alfonso Quintas Cardama
1 Jun 23